https://www.selleckchem.com/products/vx-11e.html
ly available staging tools and tumor DNA sequencing cannot identify such patients reliably and accurately. This study highlights the inaccuracy of post-NAC clinical restaging TUR with or without adjunctive tumor mutation analysis, to assess pathologic residual disease accurately. Caution must be taken when performing post-NAC restaging, especially when considering conservative management strategies such as active surveillance on this basis. Patient summary Several groups are evaluating whether certain patients, whose bladder cancer respo
Like
Comment
Share
